Evidence map›Paper›PMID 23212129›Full record

ArticleJournal of fluorescence2013

Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues.

Akram-Sadat Tabatabaei-Panah, Mahmood Jeddi-Tehrani, Roya Ghods, Mohammad-Mehdi Akhondi, Nazanin Mojtabavi, Ahmad-Reza Mahmoudi, Ebrahim Mirzadegan, Sorour Shojaeian, Amir-Hassan Zarnani

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of fluorescence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Bone Morphogenetic Protein-2 Conjugated to Quantum DotNanomaterials (Basel, Switzerland) · 2020
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akram-Sadat Tabatabaei-PanahDepartment of Biology, Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch (Ghiamdasht), Tehran, Iran.
Mahmood Jeddi-Tehrani
Roya Ghods
Mohammad-Mehdi Akhondi
Nazanin Mojtabavi
Ahmad-Reza Mahmoudi
Ebrahim Mirzadegan
Sorour Shojaeian
Amir-Hassan Zarnani

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we introduce novel optical properties and accurate sensitivity of Quantum dot (QD)-based detection system for tracking the breast cancer marker, HER2. QD525 was used to detect HER2 using home-made HER2-specific monoclonal antibodies in fixed and living HER2(+) SKBR-3 cell line and breast cancer tissues. Additionally, we compared fluorescence intensity (FI), photostability and staining index (SI) of QD525 signals at different exposure times and two excitation wavelengths with those of the conventional organic dye, FITC. Labeling signals of QD525 in both fixed and living breast cancer cells and tissue preparations were found to be significantly higher than those of FITC at 460-495 nm excitation wavelengths. Interestingly, when excited at 330-385 nm, the superiority of QD525 was more highlighted with at least 4-5 fold higher FI and SI compared to FITC. Moreover, QDs exhibited exceptional photostability during continuous illumination of cancerous cells and tissues, while FITC signal faded very quickly. QDs can be used as sensitive reporters for in situ detection of tumor markers which in turn could be viewed as a novel approach for early detection of cancers. To take comprehensive advantage of QDs, it is necessary that their optimal excitation wavelength is employed.

Indexed as

Quantum DotsAntibodies, MonoclonalBiomarkers, TumorBlotting, WesternBreast NeoplasmsCell Line, TumorEnzyme-Linked Immunosorbent AssayErb-b2 Receptor Tyrosine KinasesFemaleFluorescent Antibody TechniqueHumansLimit of DetectionAntibodies, MonoclonalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.